Argenx announces full exercise of underwriters' option to purchase additional adss

Regulated information — inside information july 19, 2023 , 11:58 pm c et july 19, 2023 , 5:58 pm et amsterdam , the netherlands — argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today that the underwriters of its previously announced global offering of ordinary shares (including ordinary shares represented by american depositary shares (“adss”)) have exercised in full their option to purchase 336,734 additional ordinary shares in the form of adss on the same terms and conditions as the global offering. this option exercise brings the anticipated total gross proceeds from the global offering to approximately $1.27 billion (approximately €1.13 billion) from the sale of an aggregate of 2,581,633 ordinary shares (including ordinary shares represented by adss).
ARGX Ratings Summary
ARGX Quant Ranking